Bibliography: Neurocognitive Disorders in Geriatric Psychiatry
This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the subject reviewed in this issue. This bibliography has been compiled by experts in the field and members of the editorial and advisory boards. Articles from the bibliography that are reprinted in this issue are in bold type.
2016
Cheng ST: Cognitive reserve and the prevention of dementia: the role of physical and cognitive activities. Curr Psychiatry Rep 2016; 18:85
Dubois B, Hampel H, Feldman HH, et al: The preclinical state of AD: preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 2016; 12:292–323
Leonpacher AK, Peters ME, Drye LT, et al: Effects of citalopram on neuropsychiatric symptoms in Alzheimer’s dementia: evidence from the CitAD Study. Am J Psychiatry 2016; 173:473–480
Martinez-Fernández R, Schmitt E, Martinez-Martin P, et al: The hidden sister of motor fluctuations in Parkinson’s disease: a review on nonmotor fluctuations. Mov Disord 2016; 31:1080–1094
Qiu WQ, Zhu H, Dean M, et al: Amyloid-associated depression and ApoE4 allele: longitudinal follow-up for the development of Alzheimer’s disease. Int J Geriatr Psychiatry 2016; 31:316–322
Reus VI, Fochtmann LJ, Eyler AE, et al: The American Psychiatric Association (2016) Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. Am J Psychiatry 2016; 173:543–546 [executive summary; full guideline at http://psychiatryonline.org/guidelines]
Safarpour D, Willis AW: Clinical epidemiology, evaluation, and management of dementia in Parkinson disease. Am J Alzheimers Dis Other Demen 2016; 31:585–594
Stankovic I, Stefanova E, Tomic A, et al: Psychiatric symptoms in the initial motor stage of Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2016; 28:205–210
2015
Bang J, Spina S, Miller BL: Frontotemporal dementia. Lancet 2015; 386:1672–1682
Bertens D, Knol DL, Scheltens P, et al: Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer’s disease. Alzheimers Dement 2015; 11:511–522
Cohen CI, Meesters PD, Zhao J: New perspectives on schizophrenia in later life: implications for treatment, policy, and research. Lancet Psychiatry 2015; 2:340–350
Edmonds EC, Delano-Wood L, Galasko DR, et al: Subtle cognitive decline and biomarker staging in preclinical Alzheimer’s disease. J Alzheimers Dis 2015; 47:231–242
Hunsberger JG, Rao M, Doraiswamy PM et al. Accelerating stem cell trials for Alzheimer's disease. Lancet Neurol 2015 Dec 15; pii: S1474-4422(15)00332-4
Kalache SM, Mulsant BH, Davies SJ, et al: The impact of aging, cognition, and symptoms on functional competence in individuals with schizophrenia across the lifespan. Schizophr Bull 2015; 41:374–381
Kim YH, Choi SH, D’Avanzo C, et al: A 3D human neural cell culture system for modeling Alzheimer’s disease. Nat Protoc 2015; 10:985–1006
Lavretsky H, Reinlieb M, St Cyr N, et al: Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015; 172:561–569
Ngandu T, Lehtisalo J, Solomon A, et al: A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015; 17:2255–2263
O’Brien JT, Thomas A: Vascular dementia. Lancet 2015; 386:1698–1706
Shmukler AB, Gurovich IY, Agius M, et al: Long-term trajectories of cognitive deficits in schizophrenia: A critical overview. Eur Psychiatry 2015; 30:1002–1010
Walker Z, Possin KL, Boeve BF, et al: Lewy body dementias. Lancet 2015; 386:1683–1697
Wang HF, Yu JT, Tang SW, et al: Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2015; 86:135–143
Weiner MW, Veitch DP, Aisen PS, et al: Impact of the Alzheimer’s Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement 2015; 11:865–884
2014
Bartels SJ, Pratt SI, Mueser KT, et al: Long-term outcomes of a randomized trial of integrated skills training and preventive healthcare for older adults with serious mental illness. Am J Geriatr Psychiatry 2014; 22:1251–1261
Doody RS, Farlow M, Aisen PS: Phase 3 trials of solanezumab and bapineuzumab for Alzheimer’s disease: Alzheimer’s Disease Cooperative Study Data Analysis and Publication Committee. N Engl J Med 2014; 370:1460
Doraiswamy PM, Sperling RA, Johnson K, et al: AV45-A11 Study Group; AV45-A11 Study Group. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry 2014; 19:1044–1051
Harvey PD: What is the evidence for changes in cognition and functioning over the lifespan in patients with schizophrenia? J Clin Psychiatry 2014; 75(Suppl 2):34–38
Marras C, Troster AI, Kulisevsky J, et al: The tools of the trade: a state of the art “How to Assess Cognition” in the patient with Parkinson's disease. Movement Disorders 2014; 29:584–596
Porsteinsson AP, Drye LT, Pollock BG, et al: Effect of citalopram on agitation in Alzheimer disease: the CITAD randomized clinical trial. JAMA 2014; 311:682–691
Rabins PV, Rovner BW, Rummans T, et al: Guideline Watch: Practice Guideline for the Treatment of Patients With Alzheimer’s Disease and Other Dementias. Arlington, VA, American Psychiatric Association, Oct 2014. http://psychiatryonline.org/guidelines
Rahimi J, Kovacs GG: Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther 2014; 6:82
Rajji TK, Miranda D, Mulsant BH: Cognition, function, and disability in patients with schizophrenia: a review of longitudinal studies. Can J Psychiatry 2014; 59:13–17
Salloway S, Sperling R, Fox NC, et al: Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014; 370:322–333
Vann Jones SA, O’Brien JT: The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med 2014; 44:673–683
Earlier Publications
Bateman RJ, Xiong C, Benzinger TL, et al: Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012; 367:795–804
Clark CM, Pontecorvo MJ, Beach TG, et al: Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 2012; 11:669–678
Devanand DP, et al: Relapse risk after discontinuation of risperidone in Alzheimer’s disease. N Engl J Med 2012; 367:1497–1507
Jack CR Jr, Albert MS, Knopman DS, et al: Introduction to the recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7:257–262
Litvan I, Aarsland D, Adler CH, et al: MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord 2011; 26:1814–1824
McKhann GM, Knopman DS, Chertkow H, et al: The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7:263–269
Prince M, et al: The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013; 9:63–75.e2
Small GW, Siddarth P, Kepe V, et al: Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Arch Neurol 2012; 69:215–222
Sperling RA, Aisen PS, Beckett LA, et al: Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7:280–292
Sperling RA, Jack CR Jr, Black SE, et al: Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement 2011; 7:367–385
Stern Y: Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol 2012; 11:1006–1012
Information & Authors
Information
Published In
History
Published in print: Winter 2017
Published online: 17 January 2017
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
There are no citations for this item
View Options
View options
PDF/ePub
View PDF/ePubGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).